A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

计划入组 420 人 · 首次发布于 2025 年 8 月 1 日

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

计划入组 15 人 · 首次发布于 2025 年 12 月 5 日

A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

计划入组 684 人 · 首次发布于 2026 年 9 月 3 日

Omburtamab

B7-H3-specific chimeric antigen receptor T cells

B7-H3-NMTi

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

Harmony Biosciences

United States

HS-20093 (GSK'227) Receives FDA and EMA Designations for Osteosarcoma and SCLC

GSK's GSK'227 Receives FDA Breakthrough Therapy Designation for Relapsed Osteosarcoma

GSK's GSK5764227 Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer